Abstract 2563
Background
Tislelizumab, an investigational humanized IgG4 monoclonal antibody with high affinity and specificity for PD-1, was engineered to minimize binding to FcgR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. It has shown robust antitumor activity and was generally well-tolerated in patients with advanced solid tumors and with classical Hodgkin lymphoma (cHL). The objectives of this analysis were to develop a population pharmacokinetics (popPK) model and quantify the impact of demographic and disease characteristics on tislelizumab PK.
Methods
PopPK analysis was conducted using pooled data from three studies (001, 102, 203) in patients with advanced solid tumors and cHL. The dataset contained 5935 PK observations from 798 patients. A nonlinear mixed-effects modeling approach with first-order conditional estimation with interaction (FOCEI) method in NONMEM was used for the analysis. Covariates related to baseline demographics, tumor type, and tumor size on tislelizumab PK were investigated. Covariates were selected using a forward addition and backward elimination method.
Results
Tislelizumab PK exhibited linearity over a dose range of 0.5 - 10 mg/kg without time‐varying clearance. A three-compartment model with first-order elimination from the central compartment, and redistribution into the peripheral compartments best described the PK of tislelizumab. Clearance (CL), volume of distribution of central compartment (Vc), and terminal half-life were estimated to be 0.164 L/day, 2.92 L, and 25.9 days, respectively. Baseline tumor size, albumin and tumor type were significant covariates on CL, while body weight, sex and tumor type were significant covariates on Vc. However, sensitivity analysis showed that the impact of these covariates on tislelizumab exposures (area under the curve, maximum and trough concentrations) was not clinically significant.
Conclusions
The final popPK model adequately described the observed tislelizumab PK. Results support the use of the current clinical dose of 200 mg Q3W and no dose adjustment is necessary based on patients’ age, body weight, race, sex, tumor type and tumor size.
Clinical trial identification
BGB-A317-Study-001: NCT02407990 BGB-A317-203: NCT03209973 BGB-A317-102: CTR20160872.
Editorial acknowledgement
Legal entity responsible for the study
BeiGene, Ltd.
Funding
BeiGene.
Disclosure
C-Y. Wu: Full / Part-time employment: BeiGene, Ltd. T. Tang: Full / Part-time employment: BeiGene, Ltd. Y. Ben: Full / Part-time employment: BeiGene, Ltd. S. Sahasranaman: Full / Part-time employment: BeiGene, Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
3088 - Spanish Survey of treatment recommendations for elderley patients with glioblastoma
Presenter: María Ángeles Vaz Salgado
Session: Poster Display session 1
Resources:
Abstract
3484 - Updated analysis of the National Registry of Nervous System Tumors in Spain (RETSINE). RETSINE: National Registry of Nervous System Tumors of the Spanish Research Group in Neuro-oncology (GEINO) and Spanish Infrequent and Orphan Tumors Group (GETHI)
Presenter: Isaac Ceballos Lenza
Session: Poster Display session 1
Resources:
Abstract
4737 - Development and validation of novel nomograms predicting survival of malignant ependymoma patients: A population-based study
Presenter: Alzhraa Abbas
Session: Poster Display session 1
Resources:
Abstract
4740 - Characteristics, incidence, and survival of primary cerebral lymphoma: A population based study
Presenter: Sherief Ghozy
Session: Poster Display session 1
Resources:
Abstract
5362 - Trends in Incidence and Survival Analyses of Adult-onset Medulloblastoma
Presenter: Feifei Lin
Session: Poster Display session 1
Resources:
Abstract
3868 - Meta of classical chemotherapy compared with high-dose chemotherapy combined with autologous stem cell transplantation in newly diagnosed medulloblastoma patients after radiotherapy
Presenter: Mengting Zhang
Session: Poster Display session 1
Resources:
Abstract
4446 - Effect of cumulative dose of maintenance temozolomide on overall survival in patients with high grade glia tumors: a single institution analysis
Presenter: Marta Nerone
Session: Poster Display session 1
Resources:
Abstract
5119 - Markers of systemic inflammation correlate with survival prognosis in patients with newly diagnosed brain metastases
Presenter: Angelika Starzer
Session: Poster Display session 1
Resources:
Abstract
3882 - Venous Thromboembolism and Intracranial Hemorrhage in Patients with High-grade Glioma
Presenter: Clara Borges
Session: Poster Display session 1
Resources:
Abstract
5152 - Comprehensive Geriatric Assessment (CGA) can categorize elderly glioblastoma (GBM) patients into three groups predicting survival: a monoinstitutional study
Presenter: Eleonora Bergo
Session: Poster Display session 1
Resources:
Abstract